@prefix dct: . @prefix biolink: . @prefix infores: . @prefix np: . @prefix npx: . @prefix orcid: . @prefix pav: . @prefix prov: . @prefix rdf: . @prefix rdfs: . @prefix sub: . @prefix tao: . @prefix this: . @prefix umls: . @prefix xsd: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { umls:C0011810 a biolink:ChemicalEntity; rdfs:label "Dextroamphetamine sulfate"; biolink:category "biolink:ChemicalEntity"; biolink:id "UMLS:C0011810" . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "Attention Deficit Disorder with Hyperactivity"; biolink:category "biolink:DiseaseOrPhenotypicFeature"; biolink:id "MONDO:0005302" . sub:_na8e63c0967774770aa886e0901005a8ab2 rdf:object ; rdf:predicate biolink:treats; rdf:subject umls:C0011810; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category "biolink:Association"; biolink:id "collaboratory:UMLS:C0011810-biolink:treats-MONDO:0005302"; biolink:publications . a biolink:Publication; biolink:category "biolink:Publication"; biolink:id "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bed3c03f4-2829-423f-a595-dc09c9cc0e40" . infores:knowledge-collaboratory a biolink:InformationResource; biolink:category "biolink:InformationResource"; biolink:id "infores:knowledge-collaboratory" . } sub:provenance { sub:_na8e63c0967774770aa886e0901005a8ab4 tao:begins_at "67"^^xsd:integer; tao:denotes ; tao:ends_at "112"^^xsd:integer; tao:has_value "Attention Deficit Disorder with Hyperactivity"; tao:part_of sub:document; a tao:text_span . sub:_na8e63c0967774770aa886e0901005a8ab6 tao:begins_at "0"^^xsd:integer; tao:denotes umls:C0011810; tao:ends_at "25"^^xsd:integer; tao:has_value "Dextroamphetamine sulfate"; tao:part_of sub:document; a tao:text_span . sub:assertion prov:generatedAtTime "2023-02-27T16:53:35.642515"^^xsd:dateTime; prov:hadPrimarySource ; prov:wasAttributedTo orcid:0000-0002-1501-1082 . sub:document tao:has_value "Dextroamphetamine sulfate tablets are indicated in: Narcolepsy and Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years)"; a tao:document_text; rdfs:seeAlso . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQD3RHyHR7WWKBYevw1qK86B6RVzI7oKlvghqXvbpOAX1KueDE6Itru34HRhrVy4OMLCRQWBE3VXktKdbgOxD3vC4cIxz5LX+XOgGWzv5WKSjOfXu/yIeJrzsuIkyHvw7/tToGrE0itJ1wGylJv+YieizmGvNiUHhP0J0+YFMNnvewIDAQAB"; npx:hasSignature "xPLfAYF36ov6tLHrPAI9T0RjKCNtHIubj3WrIissgchN+/CtvpptDPAZRG4O+XThEVTja1ap+pDk8uyze+g4kGm420KC3mWEZ2117na3v9Ow1O55/TRyYJH9Vq2IRajHORO4zNy5c5GAmbuFzk2S3WujAlvVMeaDxybjcq4d164="; npx:hasSignatureTarget this: . this: dct:conformsTo biolink:; prov:generatedAtTime "2023-02-27T16:53:35.642515"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-1501-1082 . biolink: pav:version "3.1.0" . }